Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

New England Journal of Medicine, Год журнала: 2022, Номер 387(12), С. 1089 - 1098

Опубликована: Авг. 27, 2022

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic a left ventricular ejection fraction 40% or less. Whether SGLT2 are effective in higher remains less certain.

Язык: Английский

---

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary

Journal of the American College of Cardiology, Год журнала: 2022, Номер 79(17), С. 1757 - 1780

Опубликована: Апрель 1, 2022

Язык: Английский

---

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation

Journal of the American College of Cardiology, Год журнала: 2023, Номер 83(1), С. 109 - 279

Опубликована: Ноя. 30, 2023

Язык: Английский

---

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis

Journal of the American College of Cardiology, Год журнала: 2023, Номер 81(11), С. 1076 - 1126

Опубликована: Янв. 23, 2023

Язык: Английский

---

Heart Failure With Preserved Ejection Fraction

Journal of the American College of Cardiology, Год журнала: 2023, Номер 81(18), С. 1810 - 1834

Опубликована: Апрель 19, 2023

Язык: Английский

---

2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction

Journal of the American College of Cardiology, Год журнала: 2023, Номер 81(18), С. 1835 - 1878

Опубликована: Апрель 19, 2023

Язык: Английский

---

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease

Journal of the American College of Cardiology, Год журнала: 2023, Номер 82(9), С. 833 - 955

Опубликована: Июль 20, 2023

Язык: Английский

---

Empagliflozin in acute myocardial infarction: the EMMY trial

European Heart Journal, Год журнала: 2022, Номер 43(41), С. 4421 - 4432

Опубликована: Авг. 29, 2022

Sodium-glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and death in patients with symptomatic failure. However, trials investigating effects this drug class following acute myocardial infarction are lacking.

Язык: Английский

---

Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation

New England Journal of Medicine, Год журнала: 2023, Номер 388(22), С. 2037 - 2048

Опубликована: Март 5, 2023

Data from a 5-year follow-up of outcomes after transcatheter edge-to-edge repair severe mitral regurgitation, as compared with maximal doses guideline-directed medical therapy alone, in patients heart failure are now available.We randomly assigned and moderate-to-severe or secondary regurgitation who remained symptomatic despite the use to undergo plus receive (device group) alone (control at 78 sites United States Canada. The primary effectiveness end point was all hospitalizations for through 2 years follow-up. annualized rate failure, all-cause mortality, risk death hospitalization safety, among other outcomes, were assessed 5 years.Of 614 enrolled trial, 302 device group 312 control group. 33.1% per year 57.2% (hazard ratio, 0.53; 95% confidence interval [CI], 0.41 0.68). All-cause mortality 57.3% 67.2% 0.72; CI, 0.58 0.89). Death within occurred 73.6% 91.5% those 0.44 0.64). Device-specific safety events 4 293 treated (1.4%), occurring 30 days procedure.Among therapy, valve safe led lower than alone. (Funded by Abbott; COAPT ClinicalTrials.gov number, NCT01626079.).

Язык: Английский

---

Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions

Journal of the American College of Cardiology, Год журнала: 2023, Номер 81(4), С. 413 - 424

Опубликована: Янв. 1, 2023

Heart failure (HF) is a progressive disease characterized by variable durations of symptomatic stability often punctuated episodes worsening despite continued therapy. These periods clinical are increasingly recognized as distinct phase in the history HF, termed HF (WHF). The definition WHF continues to evolve from historical focus solely on hospitalization now include nonhospitalization events (eg, need for intravenous diuretic therapy emergency or outpatient setting). Most trials date have had and death primary endpoints, only recently, some studies included other regardless location care. This article reviews evolution definition, highlights importance considering onset an event that marks new summarizes latest investigating novel therapies, outlines unmet needs regarding identification treatment WHF.

Язык: Английский

---